BIOCON Q2 FY27: REVENUE UP 2% YOY TO ₹4,389 CR, PAT FALLS 52%, EBITDA DECLINES 7%; STRONGER H2 EXPECTED ON BIOSIMILAR LAUNCHES, INSULIN CAPACITY EXPANSION & GENERICS RECOVERY

• Biosimilars: Revenue grew 3% YoY to ₹2,809 Cr; EBITDA declined 7% to ₹623 Cr, with 22% margin. • Generics: Revenue increased 10% YoY to ₹774 Cr; EBITDA surged to ₹64 Cr from ₹7 Cr, supported by improved utilisation. • Services (Syngene): Revenue declined 9% YoY to ₹833 Cr but grew 13% QoQ; EBITDA improved 51% sequentially. • H1 FY27 Performance: Revenue increased 6% YoY to ₹8,725 Cr; reported PAT surged 57% to ₹182 Cr. • US Biosimilars: Yesafili recorded encouraging launch momentum, while Yesintek continued gaining market share. • Brazil Partnership: Secured a 10-year Pertuzumab partnership with total contract value of $400 Mn. • Insulin Expansion: Additional Malaysia fill-finish capacity commissioned to support rising insulin demand. • Global Expansion: Secured approximately 20 European tender awards and launched 13 products across emerging markets. • Management Outlook: Expects stronger H2 FY27, driven by biosimilar launches, increased insulin capacity, improving Generics profitability and gradual Services recovery, with focus on cash flow and debt reduction.

BIOCON LIMITED.

← Back to feed